|
survival |
23 |
|
hepatocellular carcinoma |
22 |
|
colorectal cancer |
21 |
|
sorafenib |
19 |
|
cytology and histology |
18 |
|
medical sciences |
18 |
|
oncology medical sciences |
18 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
18 |
|
advanced hepatocellular carcinoma |
17 |
|
advanced hcc |
13 |
|
biomarker |
13 |
|
humans |
13 |
|
immunotherapy |
13 |
|
liver cancer |
13 |
|
breast cancer |
12 |
|
elderly |
12 |
|
hcc |
10 |
|
survival analysis |
10 |
|
targeted therapy |
10 |
|
11c-acetate |
9 |
|
contrast ct |
9 |
|
female |
9 |
|
hepatocellular carcinoma (hcc) |
9 |
|
hifu |
9 |
|
liver transplantation |
9 |
|
milan criteria |
9 |
|
morbidity |
9 |
|
mortality |
9 |
|
non-invasive treatment |
9 |
|
pet/ct |
9 |
|
transarterial chemoembolization |
9 |
|
adverse events |
8 |
|
bevacizumab |
8 |
|
carcinoma, hepatocellular - mortality - therapy |
8 |
|
chemoembolization, therapeutic - adverse effects - mortality |
8 |
|
child-pugh a |
8 |
|
child-pugh b |
8 |
|
gist |
8 |
|
hepatectomy |
8 |
|
hepatitis |
8 |
|
hepatitis b |
8 |
|
infusions, intra-arterial |
8 |
|
liver metastasis |
8 |
|
liver neoplasms - mortality - therapy |
8 |
|
liver resection |
8 |
|
pembrolizumab |
8 |
|
seroconversion (sc) |
8 |
|
surgery |
8 |
|
tki |
8 |
|
tyrosine-kinase inhibitor |
8 |
|
adjuvant chemotherapy |
7 |
|
anti-angiogenesis |
7 |
|
antigen expression |
7 |
|
arginase |
7 |
|
arginine |
7 |
|
cancer combination chemotherapy |
7 |
|
cancer stem cell |
7 |
|
cell invasion |
7 |
|
chemotherapy |
7 |
|
crc |
7 |
|
gastroenterology |
7 |
|
lung cancer |
7 |
|
male |
7 |
|
metastasis |
7 |
|
middle aged |
7 |
|
mir-139-3p |
7 |
|
mir-622 |
7 |
|
mirna |
7 |
|
neoplasms |
7 |
|
outcome |
7 |
|
peg-rharg1 |
7 |
|
thalidomide |
7 |
|
advanced pancreatic cancer |
6 |
|
antigenic cartography |
6 |
|
antigenic distance |
6 |
|
antigenic field |
6 |
|
asian |
6 |
|
biological therapy |
6 |
|
booster vaccine |
6 |
|
chemicals and cas registry numbers |
6 |
|
coronavirus |
6 |
|
covid-19 |
6 |
|
doxorubicin |
6 |
|
erlotinib |
6 |
|
fatal outcome |
6 |
|
gastrin |
6 |
|
gemcitabine |
6 |
|
hypothyroidism |
6 |
|
immune imprinting |
6 |
|
laparoscopic liver resection |
6 |
|
liver transplant |
6 |
|
long-term outcome |
6 |
|
lung metastasis |
6 |
|
metastases |
6 |
|
molecular targeted therapy |
6 |
|
neoplasm metastasis |
6 |
|
neuroendocrine carcinoma |
6 |
|
omeprazole |
6 |
|
omicron |
6 |
|
overall survival |
6 |
|
pancreatic tumor |
6 |
|
recurrence |
6 |
|
sars virus |
6 |
|
sars-cov-1 |
6 |
|
sars-cov-2 variants |
6 |
|
severe acute respiratory syndrome |
6 |
|
sorafenib-refractory |
6 |
|
systemic therapy |
6 |
|
thyroid diseases |
6 |
|
vaccine seed strain selection |
6 |
|
zollinger-ellison syndrome |
6 |
|
5-fu |
5 |
|
aged |
5 |
|
alpha-fetoprotein |
5 |
|
angiogenesis |
5 |
|
cancer stem cells |
5 |
|
chemoresistanc |
5 |
|
chemosensitivity |
5 |
|
chemotherapy, adjuvant |
5 |
|
cisplatin |
5 |
|
combination therapy |
5 |
|
epidemiology |
5 |
|
everolimus |
5 |
|
gsk3β |
5 |
|
hepatology |
5 |
|
human recombinant arginase |
5 |
|
incidence |
5 |
|
internal medicine |
5 |
|
liver |
5 |
|
lobectomy |
5 |
|
medicine & public health |
5 |
|
melanoma |
5 |
|
nivolumab |
5 |
|
novel therapy |
5 |
|
oxaliplatin |
5 |
|
pin1 |
5 |
|
preclinical study |
5 |
|
prediction model |
5 |
|
prevalence |
5 |
|
proctology |
5 |
|
ptk787 |
5 |
|
raf/mek/erk signaling pathway |
5 |
|
raf265 |
5 |
|
rhoa |
5 |
|
rhoc |
5 |
|
segmentectomy |
5 |
|
slit3 |
5 |
|
surrogate |
5 |
|
survivin |
5 |
|
tace |
5 |
|
tomography, x-ray computed |
5 |
|
trastuzumab |
5 |
|
trends |
5 |
|
tumorigenesis |
5 |
|
wedge resection |
5 |
|
β-catenin |
5 |
|
5-fluorouracil |
4 |
|
acute disease |
4 |
|
adult |
4 |
|
advanced cancer |
4 |
|
akt |
4 |
|
antibodies, monoclonal, humanized - pharmacology |
4 |
|
antineoplastic agents - economics - therapeutic use |
4 |
|
antineoplastic agents - pharmacology |
4 |
|
antineoplastic agents, phytogenic - adverse effects |
4 |
|
antineoplastic combined chemotherapy protocols - economics - therapeutic use |
4 |
|
arthritis, rheumatoid - chemically induced |
4 |
|
brain metastases |
4 |
|
breast neoplasms - drug therapy - enzymology - genetics - pathology |
4 |
|
cabozantinib |
4 |
|
camptothecin - adverse effects - analogs & derivatives |
4 |
|
cancer staging |
4 |
|
capecitabine |
4 |
|
checkpoint inhibitors |
4 |
|
clinical trials as topic |
4 |
|
colorectal neoplasms - drug therapy |
4 |
|
colorectal neoplasms - drug therapy - enzymology - pathology |
4 |
|
combined modality therapy |
4 |
|
consensus |
4 |
|
cost-benefit analysis |
4 |
|
drug delivery systems |
4 |
|
drug resistance, neoplasm |
4 |
|
drug therapy |
4 |
|
erbb-2 |
4 |
|
hong kong |
4 |
|
immune checkpoint inhibitors |
4 |
|
immune regulation |
4 |
|
ipilimumab |
4 |
|
liver neoplasms |
4 |
|
lymphoma |
4 |
|
mouse model |
4 |
|
mtor |
4 |
|
neoadjuvant therapy |
4 |
|
nonsmall cell lung cancer |
4 |
|
pd1 |
4 |
|
pdl1 |
4 |
|
pdl2 |
4 |
|
pi3 kinase |
4 |
|
prospective studies |
4 |
|
radiotherapy |
4 |
|
receptor, erbb-2 - antagonists & inhibitors - biosynthesis - genetics - metabolism |
4 |
|
solid tumors |
4 |
|
topoisomerase i inhibitors |
4 |
|
tyrosine kinase inhibitors |
4 |
|
xelox |
4 |
|
3-month overall survival |
3 |
|
abdominal pain |
3 |
|
adenocarcinoma - drug therapy |
3 |
|
adult wilm's tumour |
3 |
|
advanced liver cancer prognostic system |
3 |
|
anaplastic thyroid cancer |
3 |
|
angiogenesis inhibitors - therapeutic use |
3 |
|
angiosarcoma |
3 |
|
anthracycline |
3 |
|
antibodies, monoclonal - therapeutic use |
3 |
|
antibodies, monoclonal, humanized |
3 |
|
antibody |
3 |
|
antineoplastic agents - administration & dosage |
3 |
|
antineoplastic agents - therapeutic use |
3 |
|
antineoplastic agents, phytogenic - administration & dosage |
3 |
|
antineoplastic combined chemotherapy protocols - administration & dosage - adverse effects - therapeutic use |
3 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
3 |
|
breast neoplasms - secondary |
3 |
|
breast tumor |
3 |
|
cancer |
3 |
|
cancer chemotherapy |
3 |
|
carboplatin - administration & dosage |
3 |
|
carcinogenesis |
3 |
|
carcinoid |
3 |
|
carcinoma, hepatocellular - drug therapy - mortality - pathology |
3 |
|
cfi-402257 |
3 |
|
cns metastases |
3 |
|
complementary and alternative medicine |
3 |
|
cyclin d1 - metabolism |
3 |
|
cytosolic dna sensing |
3 |
|
diagnostic imaging |
3 |
|
drug toxicity |
3 |
|
ductal carcinoma in situ (dcis) |
3 |
|
etoposide - administration & dosage |
3 |
|
genetics |
3 |
|
hemangiosarcoma - drug therapy - pathology - surgery |
3 |
|
her2-positive breast cancer |
3 |
|
herbs |
3 |
|
immunodominant site |
3 |
|
immunologic factors - therapeutic use |
3 |
|
intestinal neoplasms - drug therapy |
3 |
|
intestine, small |
3 |
|
invasive ductal carcinoma (idc) |
3 |
|
ki67 |
3 |
|
kidney neoplasms - drug therapy - pathology - surgery |
3 |
|
lapatinib |
3 |
|
linear epitopes |
3 |
|
liver neoplasms - drug therapy - pathology |
3 |
|
luminal breast cancer |
3 |
|
lymphoma, mantle-cell - drug therapy - metabolism - pathology |
3 |
|
magnetic resonance imaging |
3 |
|
multiple myeloma - diagnosis - pathology |
3 |
|
neoplasm recurrence, local |
3 |
|
neratinib |
3 |
|
neuroendocrine |
3 |
|
neutralization |
3 |
|
non-small cell lung cancer |
3 |
|
pancreatic |
3 |
|
pathologic complete response |
3 |
|
pd-1 inhibitor |
3 |
|
pd-l1 |
3 |
|
pelvic neoplasms - secondary |
3 |
|
plasmacytoma - secondary |
3 |
|
platelet count |
3 |
|
prognostic score system |
3 |
|
prostatic neoplasms - drug therapy - metabolism - pathology |
3 |
|
quality of life |
3 |
|
sars-cov-2 |
3 |
|
senescence |
3 |
|
sting pathway |
3 |
|
sunitinib |
3 |
|
taxane |
3 |
|
tec |
3 |
|
thalidomide - therapeutic use |
3 |
|
transforming growth factor beta1 - metabolism |
3 |
|
treatment outcome |
3 |
|
ttk inhibitor |
3 |
|
tumor markers, biological - metabolism |
3 |
|
tyrosine kinase inhibitor |
3 |
|
unresectable hcc |
3 |
|
variants |
3 |
|
vascular endothelial growth factor a - metabolism |
3 |
|
vincristine - administration & dosage |
3 |
|
wilms tumor - drug therapy - pathology - surgery |
3 |
|
young age |
3 |
|
abdominal distension |
2 |
|
acute kidney failure |
2 |
|
adjuvant drug therapy |
2 |
|
advanced gastric cancer |
2 |
|
alanine aminotransferase blood level |
2 |
|
angiogenic pathway |
2 |
|
antineoplastic agents, hormonal - therapeutic use |
2 |
|
biomarkers |
2 |
|
breast - pathology - surgery |
2 |
|
breast neoplasms |
2 |
|
breast neoplasms - drug therapy - pathology - surgery |
2 |
|
capmatinib |
2 |
|
carcinoembryonic antigen - blood |
2 |
|
carcinoma in situ - drug therapy - radiotherapy - surgery |
2 |
|
carcinoma, ductal, breast - drug therapy - radiotherapy - surgery |
2 |
|
carcinoma, hepatocellular - secondary - therapy |
2 |
|
chemotherapy, adjuvant - methods |
2 |
|
chromosome 19q |
2 |
|
cirrhosis |
2 |
|
colorectal neoplasms - drug therapy - pathology - surgery |
2 |
|
communication |
2 |
|
computer assisted tomography |
2 |
|
decision support techniques |
2 |
|
dose-finding |
2 |
|
drug bioavailability |
2 |
|
drug withdrawal |
2 |
|
durvalumab |
2 |
|
elderly patients |
2 |
|
epidermal growth factor pathway |
2 |
|
fatigue |
2 |
|
hklc |
2 |
|
hoarseness |
2 |
|
human |
2 |
|
hyperammonaemia |
2 |
|
intraductal |
2 |
|
ki-67 |
2 |
|
letter |
2 |
|
liver cancer staging |
2 |
|
liver neoplasms - pathology - surgery |
2 |
|
mammalian target of rapamycin |
2 |
|
molecular diagnostic techniques |
2 |
|
muscle neoplasms - secondary - therapy |
2 |
|
neuroendocrine tumours |
2 |
|
non-small-cell lung cancer |
2 |
|
oncology |
2 |
|
pacific |
2 |
|
pazopanib |
2 |
|
physical activity |
2 |
|
pre-invasive |
2 |
|
predictive factors |
2 |
|
priority journal |
2 |
|
prognosis |
2 |
|
progression-free survival |
2 |
|
radiotherapy, adjuvant - methods |
2 |
|
risk assessment |
2 |
|
sbrt |
2 |
|
side effect |
2 |
|
signal transduction |
2 |
|
sunitinibs |
2 |
|
tamoxifen - therapeutic use |
2 |
|
thigh |
2 |
|
trans-arterial chemo-embolization |
2 |
|
treatment response |
2 |
|
tumor markers |
2 |
|
tumour progression |
2 |
|
upregulation |
2 |
|
voice change |
2 |
|
11q13 |
1 |
|
11q13 amplification |
1 |
|
abdominal infection |
1 |
|
accelerated approval |
1 |
|
acitretin |
1 |
|
adefovir |
1 |
|
adjuvant |
1 |
|
adjuvant therapy |
1 |
|
albumin-bilirubin score |
1 |
|
anemia |
1 |
|
anthracyclines |
1 |
|
anti-pd-1 |
1 |
|
anti-programmed death-ligand 1 |
1 |
|
antiangiogenic therapy |
1 |
|
antineoplastic activity |
1 |
|
antineoplastic protocols |
1 |
|
asbestos |
1 |
|
ascolt |
1 |
|
aspirin |
1 |
|
atezolizumab |
1 |
|
australia |
1 |
|
axitinib |
1 |
|
best supportive care |
1 |
|
biomarker testing turnaround time |
1 |
|
bullous lichen planus |
1 |
|
cancer outcomes |
1 |
|
cancer risk factors |
1 |
|
carcinoma |
1 |
|
cardiotoxicity |
1 |
|
care co-ordination |
1 |
|
cdk4/6 inhibitor |
1 |
|
celestial |
1 |
|
checkpoint inhibitor |
1 |
|
chemoradiotherapy |
1 |
|
chinese |
1 |
|
cholangiocarcinoma |
1 |
|
clinical epidemiology |
1 |
|
clinical trial |
1 |
|
clinical trial eligibility |
1 |
|
colon |
1 |
|
combination |
1 |
|
consolidation therapy |
1 |
|
cortactin/ems1 |
1 |
|
cross cultural |
1 |
|
cultural competence |
1 |
|
cyclin d1 |
1 |
|
cyclin-dependent kinase inhibitor |
1 |
|
cyp2d6 |
1 |
|
cytotoxic t-lymphocyte-associated protein-4 (ctla-4) |
1 |
|
de novo resistance |
1 |
|
depth of response |
1 |
|
diastolic function |
1 |
|
disease-free survival |
1 |
|
distant disease-free survival |
1 |
|
dose reduction |
1 |
|
dosing schedule |
1 |
|
dukes b |
1 |
|
dukes c |
1 |
|
early breast cancer |
1 |
|
early diagnosis |
1 |
|
early tumor shrinkage |
1 |
|
echocardiography |
1 |
|
egfr mutated |
1 |
|
egfr mutation |
1 |
|
ems1 |
1 |
|
endocrine therapy |
1 |
|
endopredict |
1 |
|
endoxifen |
1 |
|
epidermal growth factor receptor (egfr) |
1 |
|
epidermal growth factor receptor tyrosine kinase inhibitor |
1 |
|
erbitux |
1 |
|
exercise |
1 |
|
exploratory analysis |
1 |
|
exposure-response |
1 |
|
e–s grade |
1 |
|
fitness |
1 |
|
guidelines as topic |
1 |
|
health services |
1 |
|
hepatic fibrosis |
1 |
|
hepatitis b reactivation |
1 |
|
her2-negative |
1 |
|
hormone receptor-positive |
1 |
|
hot flashes |
1 |
|
immigrant health |
1 |
|
immigrants |
1 |
|
immune checkpoint inhibition |
1 |
|
immune checkpoint inhibitor |
1 |
|
immune-checkpoint inhibitors |
1 |
|
immunohistochemistry |
1 |
|
inc280 |
1 |
|
indirect treatment comparison |
1 |
|
inflammation |
1 |
|
lamivudine |
1 |
|
left ventricular ejection fraction |
1 |
|
left ventricular ejection fraction (lvef) |
1 |
|
liver function |
1 |
|
locally advanced nsclc |
1 |
|
lung neoplasms |
1 |
|
management |
1 |
|
matching-adjusted indirect comparison (maic) |
1 |
|
mcrc |
1 |
|
met |
1 |
|
met inhibitor |
1 |
|
metabolism |
1 |
|
metastatic breast cancer |
1 |
|
metastatic cancer |
1 |
|
metastatic non‒small-cell lung cancer |
1 |
|
migrants |
1 |
|
multi-culturalism |
1 |
|
multidisciplinary teams |
1 |
|
multimodality therapy |
1 |
|
myocardial contraction |
1 |
|
neutrophils |
1 |
|
nonsquamous non-small-cell lung cancer |
1 |
|
non‒small-cell lung cancer |
1 |
|
nsclc |
1 |
|
objective response |
1 |
|
oesophagus |
1 |
|
oncogenes |
1 |
|
optimal care pathways |
1 |
|
outcomes |
1 |
|
ovarian cancer |
1 |
|
patient-reported outcome measures |
1 |
|
patient-reported outcomes |
1 |
|
patterns of care |
1 |
|
pd-1 |
1 |
|
pd-l1 expression |
1 |
|
phase ii |
1 |
|
phenotype |
1 |
|
physical function |
1 |
|
platelets |
1 |
|
pneumonitis |
1 |
|
predictive biomarker |
1 |
|
preferences |
1 |
|
prognostic factor |
1 |
|
prognostic markers |
1 |
|
prognostic signatures |
1 |
|
programmed cell death ligand-1 |
1 |
|
programmed death ligand 1 |
1 |
|
progression free survival |
1 |
|
psychosocial |
1 |
|
pulmonary adenocarcinoma |
1 |
|
radiation therapy |
1 |
|
rate of progression |
1 |
|
real-world data |
1 |
|
real-world population |
1 |
|
rectal |
1 |
|
rectal cancer |
1 |
|
regorafenib |
1 |
|
renal cell carcinoma |
1 |
|
review |
1 |
|
safety |
1 |
|
seminoma |
1 |
|
single-gene genetic alterations |
1 |
|
social functioning |
1 |
|
spartalizumab |
1 |
|
splenic flexure colon cancer |
1 |
|
splenomegaly |
1 |
|
stage iii |
1 |
|
stage iii non–small cell lung cancer |
1 |
|
stigma |
1 |
|
stoma |
1 |
|
strain |
1 |
|
strain imaging |
1 |
|
strain rate |
1 |
|
strength |
1 |
|
supportive care |
1 |
|
surrogacy |
1 |
|
tamoxifen |
1 |
|
testis cancer |
1 |
|
three-year update |
1 |
|
thyroid disorders |
1 |
|
tissue tumor mutational burden |
1 |
|
tolerance |
1 |
|
tp53 |
1 |
|
treatment |
1 |
|
treatment decision |
1 |
|
treatment resistance |
1 |
|
treatment utilization |
1 |
|
triple-negative breast neoplasms |
1 |
|
tumor biomarkers |
1 |
|
tumor size modeling |
1 |
|
tumour microenvironment |
1 |
|
two-dimensional speckle tracking echocardiography (2dste): anthracyclines |
1 |
|
unmet needs |
1 |
|
younger women |
1 |
